Sean Laaman
Stock Analyst at Morgan Stanley
(4.68)
# 156
Out of 5,140 analysts
23
Total ratings
78.95%
Success rate
20.86%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Downgrades: Equal-Weight | $196 → $204 | $189.10 | +7.88% | 4 | Jan 8, 2026 | |
| EXEL Exelixis | Downgrades: Equal-Weight | $45 → $48 | $44.81 | +7.12% | 5 | Jan 8, 2026 | |
| BBIO BridgeBio Pharma | Initiates: Overweight | $96 | $78.15 | +22.84% | 1 | Jan 6, 2026 | |
| CERT Certara | Maintains: Equal-Weight | $16 → $12 | $9.65 | +24.35% | 2 | Dec 18, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Overweight | $20 | $11.39 | +75.59% | 1 | Dec 5, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Overweight | $34 | $16.95 | +100.59% | 1 | Nov 21, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $90 → $115 | $74.89 | +53.56% | 3 | Oct 30, 2025 | |
| RMD ResMed | Maintains: Overweight | $298 → $304 | $259.28 | +17.25% | 2 | Oct 21, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $350 → $383 | $341.64 | +12.11% | 2 | Oct 20, 2025 | |
| ALEC Alector | Assumes: Underweight | $3 → $1.5 | $1.92 | -21.88% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 | $71.71 | -6.57% | 1 | Feb 14, 2025 |
Axsome Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $196 → $204
Current: $189.10
Upside: +7.88%
Exelixis
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $45 → $48
Current: $44.81
Upside: +7.12%
BridgeBio Pharma
Jan 6, 2026
Initiates: Overweight
Price Target: $96
Current: $78.15
Upside: +22.84%
Certara
Dec 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $9.65
Upside: +24.35%
BridgeBio Oncology Therapeutics
Dec 5, 2025
Initiates: Overweight
Price Target: $20
Current: $11.39
Upside: +75.59%
MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $16.95
Upside: +100.59%
Disc Medicine
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $115
Current: $74.89
Upside: +53.56%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298 → $304
Current: $259.28
Upside: +17.25%
BeOne Medicines AG
Oct 20, 2025
Maintains: Overweight
Price Target: $350 → $383
Current: $341.64
Upside: +12.11%
Alector
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $1.92
Upside: -21.88%
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $71.71
Upside: -6.57%